Table III.

Mean Pharmacokinetic Parameters After Single-Dose Administration of CyA in Dogs

	Dog study no. 1		Dog study no. 2
	F1 (capsule 30 mg)	F2 (tablet 30 mg)	F3 (Neoral® 25 mg)	F4 (capsule 25 mg)	F5 (capsule 25 mg)	F6 (tablet 25 mg)
Cmax (µg/L)	337 (±124)	81 (±29.7)	331 (±57.4)	231 (±119)	370 (±121)	227 (±76.9)
Tmax (h)	1.25 (±0.49)	2.17 (±0.68)	0.88 (±0.25)	1.25 (±0.65)	1 (±0)	1.88 (±0.86)
AUCinf (haµg/L)	1,282 (±245)	664 (±499)b	1,269 (±256)	883 (±382)	1,267 (±265)	1,040 (±272)
Relative bioavailabilitya	–	–	1.00	0.70	1.00	0.82

All data are mean values ± SD, n = 4

^a Relative bioavailability is compared with Neoral® (F3)

^b Statistically significant difference to F1 (p < 0.01)